Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Stocks in this Quantisnow insightHealth Care
Historical context for ZVRA
Across the 8 sessions after earlier ZVRA headlines, the stock closed higher 2 times and lower 6 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ZVRA | SPY |
|---|---|---|---|
| Jan 8, 2026 | Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference | +1.8% | -0.0% |
| Dec 29, 2025 | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) | -0.6% | -0.4% |
| Dec 15, 2025 | Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | -1.9% | -0.2% |
| Dec 2, 2025 | Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD | -2.0% | +0.2% |
| Nov 21, 2025 | Zevra Therapeutics, Inc. Announces CFO Transition | -5.0% | +1.0% |
| Nov 6, 2025 | Zevra Reports Third Quarter 2025 Financial Results and Corporate Update | -9.7% | -1.1% |
Quantisnow market dataNASDAQ
ZVRA
Zevra Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ZVRA
Full ZVRA profile on Quantisnow Follow ZVRA and get a push notification the moment its next story breaks.